| Aclaris Therapeutics is a biopharmaceutical company focused on immuno-inflammatory diseases. Co.'s pipeline of drug candidates includes: ATI-450 mitogen-activated protein kinase-activated protein kinase 2 Inhibitor Oral for the indication of Rheumatoid Arthritis plus Additional Immuno-inflammatory Indication; and ATI-1777 Janus kinase (JAK)1/JAK3 Inhibitor Soft Topical for the indication of Atopic Dermatitis. ESKATA, Co.'s only U.S. Food and Drug Administration (FDA)-approved product, is a formulation of high-concentration hydrogen peroxide topical solution which is approved by the FDA as an office-based prescription treatment for raised seborrheic keratosis, a non-malignant skin tumor. We show 23 historical shares outstanding datapoints in our ACRS shares outstanding history coverage, used to compute ACRS market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ACRS market cap history over the course of time is important for investors
interested in comparing ACRS's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ACRS versus a peer is one thing; comparing
ACRS market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ACRS can fluctuate over the course of history.
With this page we aim to empower investors researching ACRS by allowing them to research the ACRS market cap history.